In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

(HealthDay News) — For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss and T2D remission, according ...

GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to ...

Research presented at the American Diabetes Association (ADA) annual meeting included a small phase I/II study on stem cell ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes ...

Endogenex To Present Data On Endoscopic Procedure For Type 2 Diabetes At American Diabetes Association's (ADA) 85Th Scientific Sessions. Date. 2025-06-17 07:46:04. Share on Facebook; ...

Endogenex to Present Data on Endoscopic Procedure for Type 2 Diabetes at American Diabetes Association’s (ADA) 85th Scientific Sessions Provided by GlobeNewswire Jun 17, 2025, 11:38:00 AM.

T1D Exchange Announces 13 Real-World Data Presentations and Posters at the American Diabetes Association (ADA) 85th Scientific Sessions. By T1D Exchange; Jun 11, 2025 ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, ...

HONG KONG, June 9, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) ...